A 38-year-old woman presents to the psychiatry outpatient clinic with a 3-month history of persistent low mood, anhedonia, and early morning awakening at 4 AM. She reports significant guilt about her past mistakes, difficulty concentrating at work, and recurrent thoughts that life is not worth living, though she denies active suicidal intent or plan. Her appetite has decreased, and she has lost 4 kg unintentionally. She has no past psychiatric history. On examination, she appears psychomotor retarded with restricted affect. What is the most appropriate first-line pharmacological intervention for this patient?

Explanation

## Diagnosis and Treatment Selection This patient meets DSM-5 criteria for Major Depressive Disorder with melancholic features (early morning awakening, psychomotor retardation, guilt, anhedonia, weight loss). The absence of psychotic features, bipolar history, or acute suicidality makes her suitable for outpatient pharmacotherapy. ### First-Line Pharmacotherapy for MDD **Key Point:** SSRIs (selective serotonin reuptake inhibitors) are the gold-standard first-line agents for MDD in the absence of specific contraindications or clinical features mandating alternative choices. **High-Yield:** Fluoxetine, sertraline, paroxetine, and citalopram are all evidence-based first-line options. Fluoxetine has the longest half-life (~4 days) and most robust clinical trial data in MDD. ### Why Fluoxetine is Optimal Here 1. **Efficacy:** SSRIs demonstrate superior efficacy and tolerability compared to tricyclic antidepressants in first-episode MDD [cite:Harrison 21e Ch 470]. 2. **Safety profile:** Lower risk of anticholinergic effects, cardiac conduction delays, and overdose toxicity compared to TCAs. 3. **Melancholic features:** SSRIs are effective for melancholic depression; some evidence suggests TCAs may have slight advantage, but SSRIs remain first-line due to safety. 4. **Dosing:** Standard starting dose is 20 mg daily; therapeutic response typically emerges at 4–6 weeks. ### Mechanism of Action Fluoxetine selectively inhibits serotonin reuptake at the presynaptic terminal, increasing synaptic serotonin availability and enhancing monoaminergic neurotransmission in mood-regulating circuits (prefrontal cortex, limbic system). ## Comparison of Options | Agent | Class | Role in MDD | Rationale for Non-Selection | |-------|-------|-------------|----------------------------| | Fluoxetine | SSRI | **First-line** | — | | Amitriptyline | TCA | Second-line | Higher anticholinergic burden, cardiac toxicity risk, weight gain; reserved for patients with concurrent chronic pain or insomnia | | Lithium | Mood stabilizer | Augmentation/bipolar | No evidence of bipolar disorder; used as adjunct in TRD, not monotherapy for unipolar MDD | | Quetiapine | Atypical antipsychotic | Augmentation/psychotic depression | No psychotic features present; monotherapy not first-line for non-psychotic MDD; metabolic side effects | **Clinical Pearl:** In melancholic MDD, some older literature favors TCAs; however, modern guidelines (APA, NICE, CANMAT) recommend SSRIs as first-line due to superior tolerability and safety, especially in older adults and those with comorbid medical conditions.